A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer
Publication
, Conference
Ellis, MJ; Dehdahti, F; Kommareddy, A; Jamalabadi-Majidi, S; Crowder, R; Jeffe, DB; Gao, F; Fleming, G; Silverman, P; Dickler, M; Carey, L; Marcom, PK
Published in: CANCER RESEARCH
January 15, 2009
Duke Scholars
Published In
CANCER RESEARCH
ISSN
0008-5472
Publication Date
January 15, 2009
Volume
69
Issue
2
Start / End Page
67S / 68S
Location
San Antonio, TX
Publisher
AMER ASSOC CANCER RESEARCH
Conference Name
31st Annual San Antonio Breast Cancer Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Ellis, M. J., Dehdahti, F., Kommareddy, A., Jamalabadi-Majidi, S., Crowder, R., Jeffe, D. B., … Marcom, P. K. (2009). A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. In CANCER RESEARCH (Vol. 69, pp. 67S-68S). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
Ellis, M. J., F. Dehdahti, A. Kommareddy, S. Jamalabadi-Majidi, R. Crowder, D. B. Jeffe, F. Gao, et al. “A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer.” In CANCER RESEARCH, 69:67S-68S. AMER ASSOC CANCER RESEARCH, 2009.
Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, et al. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. In: CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2009. p. 67S-68S.
Ellis, M. J., et al. “A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer.” CANCER RESEARCH, vol. 69, no. 2, AMER ASSOC CANCER RESEARCH, 2009, pp. 67S-68S.
Ellis MJ, Dehdahti F, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Jeffe DB, Gao F, Fleming G, Silverman P, Dickler M, Carey L, Marcom PK. A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH; 2009. p. 67S-68S.
Published In
CANCER RESEARCH
ISSN
0008-5472
Publication Date
January 15, 2009
Volume
69
Issue
2
Start / End Page
67S / 68S
Location
San Antonio, TX
Publisher
AMER ASSOC CANCER RESEARCH
Conference Name
31st Annual San Antonio Breast Cancer Symposium
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3101 Biochemistry and cell biology
- 1112 Oncology and Carcinogenesis